Search

Your search keyword '"Fliedner, Gerhard"' showing total 20 results
Start Over Author "Fliedner, Gerhard"

Refine your results

more »

more »

more »
20 results on '"Fliedner, Gerhard"'

1. A Generalised Similarity Measure for Question Answering

Author

Fliedner, Gerhard, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Montoyo, Andrés, editor, Muńoz, Rafael, editor, and Métais, Elisabeth, editor

Published
2005
Full Text
View/download PDF

2. Deriving FrameNet Representations: Towards Meaning-Oriented Question Answering

Author

Fliedner, Gerhard, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Meziane, Farid, editor, and Métais, Elisabeth, editor

Published
2004
Full Text
View/download PDF

3. ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis

Author

Specker, Christof, primary, Alberding, Annette, additional, Aringer, Martin, additional, Burmester, Gerd-Rüdiger, additional, Flacke, Jan-Paul, additional, Hofmann, Michael W., additional, Kästner, Peter, additional, Kellner, Herbert, additional, Moosig, Frank, additional, Sieburg, Maren, additional, Tony, Hans-Peter, additional, and Fliedner, Gerhard, additional

Published
2021
Full Text
View/download PDF

7. New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – implications from the prospective multicenter VADERA II study

Author

Klooster, Peter M. ten, Englbrecht, Matthias Emanuel Richard Peter, Alten, Rieke, Aringer, Martin, Baerwald, Christoph, Burkhardt, Harald, Eby, Nancy, Flacke, Jan-Paul, Fliedner, Gerhard, Henkemeier, Ulf, Hofmann, Michael W., Kleinert, Stefan, Kneitz, Christian, Krüger, Klaus, Pohl, Christoph, Schett, Georg, Schmalzing, Marc, Tausche, Anne-Kathrin, Tony, Hans-Peter, Wendler, Jörg, Klooster, Peter M. ten, Englbrecht, Matthias Emanuel Richard Peter, Alten, Rieke, Aringer, Martin, Baerwald, Christoph, Burkhardt, Harald, Eby, Nancy, Flacke, Jan-Paul, Fliedner, Gerhard, Henkemeier, Ulf, Hofmann, Michael W., Kleinert, Stefan, Kneitz, Christian, Krüger, Klaus, Pohl, Christoph, Schett, Georg, Schmalzing, Marc, Tausche, Anne-Kathrin, Tony, Hans-Peter, and Wendler, Jörg

Abstract

Objectives: To investigate the prevalence of depressive symptoms in rheumatoid arthritis (RA) patients using two previously validated questionnaires in a large patient sample, and to evaluate depressive symptoms in the context of clinical characteristics (e.g. remission of disease) and patient-reported impact of disease. Methods: In this cross-sectional study, the previously validated Patient Health Questionnaire (PHQ-9) and Beck-Depression Inventory II (BDI-II) were used to assess the extent of depressive symptoms in RA patients. Demographic background, RA disease activity score (DAS28), RA impact of disease (RAID) score, comorbidities, anti-rheumatic therapy and antidepressive treatment, were recorded. Cut-off values for depressive symptomatology were PHQ-9 ≥5 or BDI-II ≥14 for mild depressive symptoms or worse and PHQ-9 ≥ 10 or BDI-II ≥ 20 for moderate depressive symptoms or worse. Prevalence of depressive symptomatology was derived by frequency analysis while factors independently associated with depressive symptomatology were investigated by using multiple logistic regression analyses. Ethics committee approval was obtained, and all patients provided written informed consent before participation. Results: In 1004 RA-patients (75.1% female, mean±SD age: 61.0±12.9 years, mean disease duration: 12.2±9.9 years, DAS28 (ESR): 2.5±1.2), the prevalence of depressive symptoms was 55.4% (mild or worse) and 22.8% (moderate or worse). Characteristics independently associated with depressive symptomatology were: age <60 years (OR = 1.78), RAID score >2 (OR = 10.54) and presence of chronic pain (OR = 3.25). Of patients classified as having depressive symptoms, only 11.7% were receiving anti-depressive therapy. Conclusions: Mild and moderate depressive symptoms were common in RA patients according to validated tools. In routine clinical practice, screening for depression with corresponding follow-up procedures is as relevant as incorporating these results with patient-reporte

Published
2019

8. SAT0163 LOW CARDIOVASCULAR EVENT RATE DURING TOCILIZUMAB TREATMENT IN THE NON-INTERVENTIONAL STUDY ICHIBAN

Author

Specker, Christof, primary, Alberding, Annette, additional, Aringer, Martin, additional, Burmester, Gerd Rüdiger, additional, Hofmann, Michael W., additional, Kästner, Peter, additional, Kellner, Herbert, additional, Luig, Christina, additional, Moosig, Frank, additional, Sieburg, Maren, additional, Tony, Hans-Peter, additional, and Fliedner, Gerhard, additional

Published
2019
Full Text
View/download PDF

9. New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – Implications from the prospective multicenter VADERA II study

Author

Englbrecht, Matthias, primary, Alten, Rieke, additional, Aringer, Martin, additional, Baerwald, Christoph G., additional, Burkhardt, Harald, additional, Eby, Nancy, additional, Flacke, Jan-Paul, additional, Fliedner, Gerhard, additional, Henkemeier, Ulf, additional, Hofmann, Michael W., additional, Kleinert, Stefan, additional, Kneitz, Christian, additional, Krüger, Klaus, additional, Pohl, Christoph, additional, Schett, Georg, additional, Schmalzing, Marc, additional, Tausche, Anne-Kathrin, additional, Tony, Hans-Peter, additional, and Wendler, Jörg, additional

Published
2019
Full Text
View/download PDF

10. Effektive und sichere Tocilizumab i.v. Therapie bei Rheumatoider Arthritis (RA), unabhängig vom eingesetzten sDMARD (MTX oder LEF)

Author

Specker, Christof, Kaufmann, Jörg, Kellner, Herbert, Kästner, Peter, Volberg, Christoph, Braunewell, Verena, Aringer, Martin, Sieburg, Maren, Meier, Lothar, Hofmann, Michael W., Flacke, Jan-Paul, Tony, Hans-Peter, and Fliedner, Gerhard

Subjects
IL-6-Rezeptorblockade, ddc: 610, Rheumatoide Arthritis, Tocilizumab i.v, 610 Medical sciences, Medicine, nicht-interventionelle Studie
Abstract

Einleitung: Tocilizumab (TCZ) wurde in klinischen Studien primär mit und ohne Methotrexat (MTX) Begleitmedikation untersucht. In der klinischen Praxis werden auch andere sDMARD Kombinationspartner (z.B. Leflunomid, LEF) eingesetzt. In der aktuellen Interimsanalyse (Stichtag 03.12.2015) der nicht-interventionellen[zum vollständigen Text gelangen Sie über die oben angegebene URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2016

11. Effektives Ansprechen und andauernde DAS28-BSG Remission unter einer Tocilizumab i.v.-Therapie bei Patienten mit Rheumatoider Arthritis (RA)

Author

Specker, Christof, Kaufmann, Jörg, Kellner, Herbert, Kästner, Peter, Volberg, Christoph, Braunewell, Verena, Aringer, Martin, Sieburg, Maren, Meier, Lothar, Hofmann, Michael W., Flacke, Jan-Paul, Tony, Hans-Peter, and Fliedner, Gerhard

Subjects
IL-6-Rezeptorblockade, ddc: 610, Rheumatoide Arthritis, Tocilizumab i.v, 610 Medical sciences, Medicine, nicht-interventionelle Studie
Abstract

Einleitung: In klinischen Studien erzielte Tocilizumab (TCZ) mit und ohne sDMARD Begleittherapie eine vergleichbare Wirksamkeit. In dieser Interimsanalyse der nicht-interventionellen Studie ICHIBAN wurde untersucht: Unterscheiden sich die Schnelligkeit im Erreichen sowie die Dauer einer DAS28-BSG Remission[zum vollständigen Text gelangen Sie über die oben angegebene URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2016
Full Text
View/download PDF

12. RheumaDATA: Vergleich von Schmerzen, Fatigue und Schlafstörungen bei 631 Patienten mit Rheumatoider Arthritis unter Biologikatherapie (Abatacept, Adalimumab, Etanercept und Tocilizumab)

Author

Aries, Peer, Neuwirth, Joachim, Fliedner, Gerhard, Amberger, Christopher, Braunewell, Verena, Wagener, Peter, Kapelle, Andreas, Jacki, Swen Holger, Krüger, Klaus, Karger, Thomas, Stille, Carsten, Köhler, Lars, Hübner, Georg, Schoo, Ulrich, Wassenberg, Siegfried, Nüßlein, Hubert G., Strothmeyer, Harald, and Brandt-Jürgens, Jan

Subjects
Versorgungsforschung, PRO, ddc: 610, Rheumatoide Arthritis, Biologika, 610 Medical sciences, Medicine, Schmerz, Fatigue
Abstract

Einleitung: Entsprechend des IQWIG gibt es für jeden der zugelassenen biologischen Wirkstoffe einen Beleg, einen Hinweis oder mindestens Anhaltspunkte für einen Nutzen bei der Rheumatoiden Arthritis in Bezug auf mindestens ein Zielkriterium. Es wurde angemerkt, dass Langzeitdaten und ausreichende[zum vollständigen Text gelangen Sie über die oben angegebene URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2016
Full Text
View/download PDF

13. Wirksamkeit einer Tocilizumab-Therapie auf die inflammatorische Anämie bei Patienten mit Rheumatoider Arthritis (RA)

Author

Specker, Christof, Kaufmann, Jörg, Kästner, Peter, Kellner, Herbert, Schwarze, Ilka, Sieburg, Maren, Vollmer, M. A., Körber, Helge, Hofmann, Michael W., Flacke, Jan-Paul, and Fliedner, Gerhard

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Gemäß WHO-Definition leiden ca. 15% aller Patienten mit rheumatoider Arthritis (RA) unter einer Anämie (Hämoglobin, 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2015
Full Text
View/download PDF

14. Optimierung der Umrechnungsformel von FFbH- in HAQ-Werte

Author

Huscher, Dörte, Specker, Christof, Fliedner, Gerhard, Albrecht, Katinka, Bischoff, Sascha, Thiele, Katja, Krause, Andreas, Schuch, Florian, Alten, Rieke H.-E., and Zink, Angela

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Während international der Health Assessment Questionnaire (HAQ, Wertebereich 0-3) zur Funktionsbewertung bei Patienten mit rheumatoider Arthritis (RA) Standard ist, wird im deutschsprachigen Raum häufig der Funktionsfragebogen Hannover (FFbH) genutzt. Lautenschläger et al.[zum vollständigen Text gelangen Sie über die oben angegebene URL], 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2015

15. RheumaDATA: Versorgungsforschung für die Rheumatoide Arthritis

Author

Aries, Peer, Wassenberg, Siegfried, Fliedner, Gerhard, Amberger, Christopher, Volberg, Christoph, Neuwirth, Joachim, and Braner, Axel

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Patient reported outcomes (PRO) erhalten eine zunehmende Bedeutung für die Bewertung des Nutzens neuer Therapien. Auch das IQWIG hat in seiner Bewertung der Zweitlinientherapie für die Rheumatoide Arthritis (RA) die Bedeutung und gleichzeitig auch den Mangel an PRO´s bei[zum vollständigen Text gelangen Sie über die oben angegebene URL], 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2015

16. Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge

Author

Englbrecht, Matthias, primary, Alten, Rieke, additional, Aringer, Martin, additional, Baerwald, Christoph G., additional, Burkhardt, Harald, additional, Eby, Nancy, additional, Fliedner, Gerhard, additional, Gauger, Bettina, additional, Henkemeier, Ulf, additional, Hofmann, Michael W., additional, Kleinert, Stefan, additional, Kneitz, Christian, additional, Krueger, Klaus, additional, Pohl, Christoph, additional, Roske, Anne-Eve, additional, Schett, Georg, additional, Schmalzing, Marc, additional, Tausche, Anne-Kathrin, additional, Peter Tony, Hans, additional, and Wendler, Joerg, additional

Published
2016
Full Text
View/download PDF

17. Measurement of individual critical differences in activity of Rheumatoid Arthritis: Confirmation and usage of DAS28-dcrit in Tocilizumab-treated patients with RA

Author

Behrens, Frank, Köhm, Michaela, Specker, Christof, Fliedner, Gerhard, Hofmann, Michael W., Lüthje, Rasmus, and Burkhardt, Harald Louis

Subjects
Krankheitsaktivität, ddc: 610, Rheumatoide Arthritis, DAS28, DAS28-dcrit, 610 Medical sciences, Medicine
Abstract

Background: Normal fluctuations in disease-activity measurements are issues for evaluation of a therapeutic-response in daily practice in rheumatoid arthritis (RA) patients. To address this aspect we established a statistical approach to determine a critical difference (dcrit) that defines valid criterion[for full text, please go to the a.m. URL], 42. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 28. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 24. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2014
Full Text
View/download PDF

18. Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge.

Author

Englbrecht, Matthias, Alten, Rieke, Aringer, Martin, Baerwald, Christoph G., Burkhardt, Harald, Eby, Nancy, Fliedner, Gerhard, Gauger, Bettina, Henkemeier, Ulf, Hofmann, Michael W., Kleinert, Stefan, Kneitz, Christian, Krueger, Klaus, Pohl, Christoph, Roske, Anne-Eve, Schett, Georg, Schmalzing, Marc, Tausche, Anne-Kathrin, Peter Tony, Hans, and Wendler, Joerg

Subjects
DIAGNOSIS of mental depression, RHEUMATOID arthritis, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, PSYCHOLOGICAL tests, PSYCHOMETRICS, QUESTIONNAIRES, RESEARCH, RESEARCH evaluation, EVALUATION research, STANDARDS, PSYCHOLOGY
Abstract

Objective: To validate standard self-report questionnaires for depression screening in patients with rheumatoid arthritis (RA) and compare these measures to one another and to the Montgomery-Åsberg Depression Rating Scale (MADRS), a standardized structured interview.Methods: In 9 clinical centers across Germany, depressive symptomatology was assessed in 262 adult RA patients at baseline (T0) and at 12 ± 2 weeks followup (T1) using the World Health Organization 5-Item Well-Being Index (WHO-5), the Patient Health Questionnaire (PHQ-9), and the Beck Depression Inventory II (BDI-II). The construct validity of these depression questionnaires (using convergent and discriminant validity) was evaluated using Spearman's correlations at both time points. The test-retest reliability of the questionnaires was evaluated in RA patients who had not undergone a psychotherapeutic intervention or received antidepressants between T0 and T1. The sensitivity and the specificity of the questionnaires were calculated using the results of the MADRS, a structured interview, as the gold standard.Results: According to Spearman's correlation coefficients, all questionnaires met convergent validity criteria (ρ > |0.50|), with the BDI-II performing best, while correlations with age and disease activity for all questionnaires met the criteria for discriminant validity (ρ < |0.50|). The only questionnaire to meet the predefined retest reliability criterion (ρ ≥ 0.70) was the BDI-II (rs  = 0.77), which also achieved the best results for both sensitivity and specificity (>80%) when using the MADRS as the gold standard.Conclusion: The BDI-II best met the predefined criteria, and the PHQ-9 met most of the validity criteria, with lower sensitivity and specificity. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

19. A Generalised Similarity Measure for Question Answering.

Author

Montoyo, Andrés, Muñoz, Rafael, Métais, Elisabeth, and Fliedner, Gerhard

Abstract

We define the Generalised Similarity Measure (GSM) as a means of uniformly and efficiently storing linguistic information to search for answers in Question Answering (QA) systems. It computes the similarity between a question representation and those of possible answers in a document collection as a database query. Linguistic knowledge from different sources can be used and combined in the GSM, allowing to find matches even with imperfect representations. To show the viability of the concept, we have implemented the GSM in a proof-of-concept QA system for German, employing information from WordNet and FrameNet. First experiments have been promising, large-scale tests are underwayThis is ongoing work in the Collate project, funded by the German Ministry for Education and Research, Grant numbers 01 IN A01 B and 01 IN C02.. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

20. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age.

Author

Specker C, Aringer M, Burmester GR, Killy B, Hofmann MW, Kellner H, Moosig F, Tony HP, and Fliedner G

Subjects
Aged, Comorbidity, Glucocorticoids therapeutic use, Humans, Middle Aged, Prospective Studies, Treatment Outcome, Antibodies, Monoclonal, Humanized adverse effects, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid epidemiology
Abstract

Objectives: To examine the safety and effectiveness of long-term tocilizumab treatment in elderly patients with rheumatoid arthritis (RA) and patients with age-associated comorbidities., Methods: ICHIBAN (NCT01194401) was a prospective, non-interventional study that observed adult patients with active moderate-to-severe RA in German rheumatology clinics and practices for up to two years. Patients were to be treated according to the tocilizumab label. Here, we present safety and effectiveness data analysed according to patient age., Results: Of the 3,164 patients treated with at least one dose of tocilizumab, 924 patients were <50 years old, 1496 patients were 50-65 years old, and 744 patients were >65 years old at baseline. Patients >65 years had the highest baseline DAS28-ESR, CDAI, and HAQ-DI scores, along with the highest burden of comorbidities, such as diabetes, coronary heart disease, anaemia, and renal insufficiency. Under treatment with tocilizumab, patients >65 years had similar improvements in DAS28-ESR, CDAI and patient-reported outcomes (fatigue, pain, sleeplessness) with similar glucocorticoid savings compared to patient groups <65 years. Patients >65 years with late-onset RA achieved similar reductions in disease activity compared to early-onset patients. Despite numerically higher rates of adverse events (AEs), serious AEs and serious infections in patients >65 years, there were similar rates of AEs leading to withdrawal., Conclusions: Elderly patients in ICHIBAN experienced improvements similar to younger patients in most effectiveness endpoints with only slightly higher rates of AEs, indicating an overall net-positive risk-benefit ratio of tocilizumab treatment regardless of patient age.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results